{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:26:43Z","timestamp":1786991203646,"version":"build-2736575974"},"reference-count":26,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2004,6,1]],"date-time":"2004-06-01T00:00:00Z","timestamp":1086048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,8,22]],"date-time":"2013-08-22T00:00:00Z","timestamp":1377129600000},"content-version":"vor","delay-in-days":3369,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2004,6]]},"DOI":"10.1016\/j.jacc.2004.02.051","type":"journal-article","created":{"date-parts":[[2004,6,11]],"date-time":"2004-06-11T16:16:34Z","timestamp":1086970594000},"page":"2183-2190","source":"Crossref","is-referenced-by-count":107,"title":["A dose-finding study of fondaparinux in patients with non\u2013ST-segment elevation acute coronary syndromes"],"prefix":"10.1016","volume":"43","author":[{"given":"Maarten L.","family":"Simoons","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge W.G.","family":"Bobbink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Boland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Gardien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Klootwijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthonie W.A.","family":"Lensing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Witold","family":"Ruzyllo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor A.W.M.","family":"Umans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alec","family":"Vahanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frans","family":"Van De Werf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Zeymer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2004.02.051_BIB1","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1053\/euhj.2002.3385","article-title":"Management of acute coronary syndromes","volume":"23","author":"Bertrand","year":"2002","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2004.02.051_BIB2","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0140-6736(02)07442-1","article-title":"Platelet glycoprotein IIb\/IIIa inhibitors in acute coronary syndromes","volume":"19","author":"Boersma","year":"2002","journal-title":"Lancet"},{"issue":"Suppl 2","key":"10.1016\/j.jacc.2004.02.051_BIB3","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1093\/ajhp\/58.suppl_2.S14","article-title":"Fondaparinux sodium","volume":"58","author":"Bauer","year":"2001","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.jacc.2004.02.051_BIB4","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1056\/NEJM200103013440901","article-title":"A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement","volume":"344","author":"Turpie","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2004.02.051_BIB5","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1056\/NEJMoa011100","article-title":"Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery","volume":"345","author":"Eriksson","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2004.02.051_BIB6","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJMoa011099","article-title":"Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery","volume":"345","author":"Bauer","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2004.02.051_BIB7","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S0140-6736(02)08648-8","article-title":"Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery","volume":"359","author":"Turpie","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2004.02.051_BIB8","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/S0140-6736(02)08652-X","article-title":"Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery","volume":"359","author":"Lassen","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2004.02.051_BIB9","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1053\/euhj.2001.2777","article-title":"A synthetic factor-Xa inhibitor (ORG31540\/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction","volume":"22","author":"Coussement","year":"2001","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2004.02.051_BIB10","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1161\/01.CIR.98.14.1358","article-title":"Reduction of recurrent ischemia with abciximab during continuous ECG-ischemia monitoring in patients with unstable angina refractory to standard treatment (CAPTURE)","volume":"98","author":"Klootwijk","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2004.02.051_BIB11","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1053\/euhj.2001.2750","article-title":"Recurrent ischaemia during continuous multilead ST-segment monitoring identifies patients with acute coronary syndromes at high risk of adverse cardiac events","volume":"22","author":"Akkerhuis","year":"2001","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2004.02.051_BIB12","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/S0735-1097(97)00094-6","article-title":"Dose-ranging trial of enoxaparin for unstable angina","volume":"29","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2004.02.051_BIB13","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJM199708143370702","article-title":"Comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease","volume":"337","author":"Cohen","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2004.02.051_BIB14","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1161\/01.CIR.100.15.1593","article-title":"Enoxaparin prevents death and cardiac ischemic events in unstable angina\/non\u2013Q-wave myocardial infarction","volume":"12","author":"Antman","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2004.02.051_BIB15","first-page":"1502","article-title":"Myocardial infarction redefined\u2014a consensus document of the Joint European Society of Cardiology\/American College of Cardiology Committee for the Redefinition of Myocardial Infarction","volume":"2121","year":"2000","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2004.02.051_BIB16","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/0140-6736(90)92336-G","article-title":"Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary disease","volume":"336","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2004.02.051_BIB17","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1056\/NEJM198810273191701","article-title":"Aspirin, heparin, or both to treat acute unstable angina","volume":"319","author":"Theroux","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2004.02.051_BIB18","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0140-6736(96)91270-2","article-title":"Low-molecular-weight heparin during instability in coronary artery disease","volume":"347","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2004.02.051_BIB19","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1016\/S0140-6736(00)02324-2","article-title":"Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation","volume":"355","author":"Eikelboom","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2004.02.051_BIB20","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation","volume":"345","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2004.02.051_BIB21","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/S0140-6736(02)08660-9","article-title":"Fondaparinux","volume":"359","author":"Bounaneaux","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2004.02.051_BIB22","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1136\/bmj.324.7348.1240","article-title":"How whistleblowing cost one doctor 550000 pounds","volume":"324","author":"Sheldon","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2004.02.051_BIB23","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1056\/NEJM199805213382102","article-title":"Inhibition of the platelet glycoprotein IIb\/IIIA receptor with tirofiban in unstable angina and non\u2013Q-wave myocardial infarction","volume":"338","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2004.02.051_BIB24","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJM199808133390704","article-title":"Inhibition of platelet glycoprotein IIb\/IIIA with eptifibatide in patients with acute coronary syndromes","volume":"339","year":"1998","journal-title":"N Eng J Med"},{"key":"10.1016\/j.jacc.2004.02.051_BIB25","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(00)05060-1","article-title":"Effect of glycoprotein IIb\/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularization","volume":"357","author":"Simoons","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2004.02.051_BIB26","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1053\/euhj.2001.2751","article-title":"Oral glycoprotein IIb\/IIIa receptor inhibitors in patients with cardiovascular disease","volume":"23","author":"Leebeek","year":"2002","journal-title":"Eur Heart J"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109704006849?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109704006849?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T08:00:43Z","timestamp":1585814443000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109704006849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2004,6]]}},"alternative-id":["S0735109704006849"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2004.02.051","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2004,6]]}}}